Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study [PDF]
AIM: To evaluate waiting list (WL) registration and liver transplantation (LT) rates in patients with hepatitis C virus (HCV)-related cirrhosis since the introduction of direct-acting antivirals (DAAs).
Angeli, Paolo +10 more
core +1 more source
New horizons in hepatitis C antiviral therapy with direct-acting antivirals [PDF]
Abstract Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites ...
Aghemo, Alessio, De Francesco, Raffaele
openaire +2 more sources
Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela +4 more
core +1 more source
Hepatitis C at presentation in a newly diagnosed infant with B Acute Lymphoblastic Leukemia
We report the unique case of a nine-month old patient diagnosed with B- Cell Acute Lymphoblastic Leukemia also positive for Hepatitis C virus, genotype 3 and a high viral load.
Qurratulain Shahood Ahmed +3 more
doaj +1 more source
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. [PDF]
Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three
Burra, Patrizia +2 more
core +1 more source
Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally
Tatsuo Kanda +11 more
doaj +1 more source
Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients [PDF]
BACKGROUND: Microbial translocation from the gut lumen has been involved in the pathogenesis of liver damage in hepatitis C virus (HCV) infection. AIM: To investigate the impact of direct-acting antiviral treatment on microbial translocation and T ...
Baroncelli, Silvia +10 more
core +1 more source
Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients
Hepatitis C virus (HCV) infection is highly prevalent among patients on haemodialysis and leads to a poorer prognosis compared to patients who do not have said infection.
Soraya Abad +9 more
doaj +1 more source
Self-reported experience in patients treated with Hepatitis C direct acting antivirals [PDF]
Background and objective: To learn about and analyze the self-reported treatment experience of HCV patients who started treatment with direct acting antivirals agents (DAA), at a real-time, proactive and integrated into the pharmaceutical care healthcare
Irene Cañamares Orbis +5 more
doaj +1 more source
Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. [PDF]
BACKGROUND & AIM: concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following directly acting antiviral (DAA) therapy in cirrhotic patients with a prior complete oncological response have been raised. Data regarding the impact of
Angeli, Paolo +16 more
core +1 more source

